Pharmacielo (PCLO.V) Stock Price

Pharmacielo Price

TSX·CLOSED
0.05
​
Market closed

Over the last 6 years Pharmacielo grew revenue by 21.5% annually, reaching 2.54 M CAD. For Pharmacielo, the net margin of -141.1% is up versus -1,383.9% a few years ago.

Pharmacielo stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pharmacielo business model & stock analysis

Pharmacielo Ltd is a company specializing in the production of medical cannabis products. The company is based in Canada, but its production facilities are located in Colombia, one of the most important cultivation areas for cannabis worldwide. The company was founded in 2014 by individuals with experience in commercial cultivation of crops. Its goal is to establish a safe and efficient production of medical cannabis in Colombia to ensure high-quality and affordable supply for patients worldwide. Pharmacielo Ltd's business model is based on the production and delivery of medical cannabis products to customers worldwide. The company produces cannabis flowers, extracts, and oils that are used to treat various medical conditions such as cancer, chronic pain, and neurological disorders. Pharmacielo Ltd works closely with the Colombian government to regulate and standardize the cultivation of medical cannabis to ensure high quality and purity of its products. The company has already received various certifications and approvals confirming the quality and safety of its products. Pharmacielo Ltd is divided into different divisions specializing in production and logistics. The "Production" division is responsible for the cultivation and harvesting of cannabis. Pharmacielo Ltd collaborates with various partners to ensure a large production capacity. The "Extraction" division is responsible for the production of medical cannabis extracts and oils. The dried cannabis flowers are dissolved in a liquid and then extracted to isolate the desired components. The "Logistics" division is responsible for the delivery of products to customers worldwide. The company works with various shipping service providers to ensure fast and reliable delivery of its products. Pharmacielo Ltd offers a wide range of products made from medical cannabis, including cannabis flowers in different varieties and sizes that can be selected based on individual needs. Additionally, products such as oils, extracts, and capsules are offered, which have a higher concentration of cannabinoids and are therefore particularly suitable for the treatment of serious illnesses such as cancer or epilepsy. Overall, Pharmacielo Ltd has become a leading company in the production and delivery of medical cannabis in recent years. The company works closely with the government and other companies to ensure a safe and reliable supply for patients worldwide. With its wide range of products and innovative production technology, Pharmacielo Ltd is well positioned to continue growing and meeting the needs of customers in the future.

Frequently asked questions about Pharmacielo

The business model of Pharmacielo Ltd focuses on the cultivation, production, and distribution of medicinal-grade cannabis oil extracts and related products. As a leading global company in the cannabis industry, Pharmacielo Ltd aims to supply high-quality medicinal cannabis extracts to meet the increasing global demand. By leveraging their expertise in agriculture, pharmaceuticals, and innovation, Pharmacielo Ltd strives to deliver safe and effective cannabis-based medical solutions. With their vertically integrated operations, which include cultivation facilities, extraction labs, and distribution networks, the company is optimizing its supply chain to ensure consistent product quality, while also expanding its market reach to serve patients and healthcare providers across the globe.

Pharmacielo Ltd is primarily active in the cannabis industry.

Some of the main competitors of Pharmacielo Ltd in the market include Canopy Growth Corporation, Aurora Cannabis Inc., and Aphria Inc.

Pharmacielo Ltd is a leading global company in the cannabis industry. Founded in 2017, Pharmacielo has quickly gained prominence due to its strategic presence in Colombia, where it leverages the ideal climate and low-cost production advantages for cannabis cultivation. The company is focused on the cultivation, processing, and production of high-quality medicinal-grade cannabis oils and extracts. With a commitment to sustainability and innovation, Pharmacielo has established itself as a reliable producer and supplier of cannabis products, meeting the growing demand for medical cannabis globally. Emphasizing rigorous quality control and compliance with international standards, Pharmacielo Ltd strives to be a market leader in the rapidly expanding cannabis industry.

Pharmacielo Ltd has achieved several significant milestones. Firstly, the company obtained its medical cannabis cultivation license in Colombia, allowing it to cultivate and process cannabis plants. Additionally, Pharmacielo secured its Good Manufacturing Practices (GMP) certification, indicating adherence to quality and safety standards in pharmaceutical manufacturing. The company successfully exported its first commercial shipment of medicinal cannabis oil to Canada, marking a crucial step in expanding its international market presence. Furthermore, Pharmacielo received approval to cultivate and process cannabis in Portugal, enabling access to the European Union market. These achievements demonstrate Pharmacielo's commitment to becoming a global leader in the medicinal cannabis industry.

Pharmacielo Ltd is primarily present in Colombia, which serves as its main operating base and headquarters. With a focus on medicinal-grade cannabis, Pharmacielo is one of the leading companies in the country's rapidly growing cannabis industry. Additionally, the company has expanded its presence into other key regions such as Peru and Uruguay, further establishing its footprint in the Latin American market. As Pharmacielo continues to expand its operations, it remains dedicated to producing high-quality cannabis products and driving innovation in the global cannabis industry.

Pharmacielo Ltd represents a strong set of values and corporate philosophy in its operations. The company is committed to providing high-quality pharmaceutical-grade cannabis products to improve people's lives. Pharmacielo focuses on sustainability, innovation, and research to ensure the highest standards of cultivation and production. With a customer-centric approach, Pharmacielo strives to deliver value and satisfaction to its stakeholders. The company embraces transparency, integrity, and accountability, promoting ethical practices throughout its operations. Pharmacielo Ltd's dedication to excellence and its commitment to improving the well-being of individuals make it a leading player in the cannabis industry.

6 analysts currently rate the Pharmacielo stock: 5 recommend buying, 1 holding and 0 selling.

Converted at the current exchange rate, the Pharmacielo share trades at 0.03 EUR (0.05 CAD).

The Pharmacielo share (PCLO.V) is listed on 2 stock exchanges, including: Toronto (PCLO.V).

Pharmacielo Ltd is a Canadian company specialized in the production and sale of medical cannabis. They operate in three different areas: cultivation, processing, and distribution of cannabis products. The company focuses on vertical integration to ensure a high-quality production chain. They have cultivation areas in Colombia, which provide ideal conditions due to the tropical climate. Continuous monitoring and inspections by both the company and government agencies secure the cultivation areas. The processing of the cannabis flowers and harvest takes place in a state-of-the-art facility certified according to international standards. Different technologies are employed to produce a high-quality end product. In the distribution sector, Pharmacielo offers various products based on medical cannabis, including oils, extracts, tinctures, suppositories, and capsules. The company's aim is to produce high-quality standardized products to ensure consistent product quality. Pharmacielo sells its products to end customers as well as wholesalers who further distribute the products. Pharmacielo's business model is based on a wholesale approach. This means that the company produces products at a wholesale level and sells them to other companies that resell the products under their own name or as the Pharmacielo brand. This relieves Pharmacielo from the distribution costs, which are taken over by the other companies. The advantage of the wholesale business model is that it allows the company to distribute its products on a broader scale while bearing only a fraction of the costs that individual sales would entail. To continue their success, Pharmacielo focuses on developing new products and expanding into new markets. The company relies on its expertise and knowledge in the production of medical cannabis. The aim is to expand the range of roll-on organic certified oils, tinctures, and capsules in order to better meet customer needs. Expanding the product offering is also an important step to differentiate from competitors and tap into new customers and markets. All in all, we can say that Pharmacielo is a profitable company that has established itself in the market for medical cannabis. They have a vertically integrated production chain that allows them to continuously produce high-quality products. The wholesale business model enables Pharmacielo to distribute its products widely and save costs. Expanding the product offering and entering new markets are the keys to the company's growth.

The revenue cannot currently be calculated for Pharmacielo.

The profit cannot currently be calculated for Pharmacielo.

The P/E ratio cannot be calculated for Pharmacielo at the moment.

The P/S cannot be calculated for Pharmacielo currently.

The Eulerpool Quality Score for Pharmacielo is 3/10.

The ISIN of Pharmacielo is CA71716K1012. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Pharmacielo is A2PCAX. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Pharmacielo is PCLO.V. The ticker symbol is used to trade Pharmacielo shares on the stock exchange.

Fair ValueTerminal
0.04 CAD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
9,463.56 CAD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
CAD
Initial public offering
Jan 30, 2018
ISIN
CA71716K1012
Cusip
71716K101
Sedol
BH4KPJ8
Market capitalization
8.72 M CADMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
1.36
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
32.58 %
Last updated Nov 5, 2026, 3:40 AM

Pharmacielo Ticker

OTC · PCLOFTSX · PCLO.V

Pharmacielo FIGI

PCLO:CN · BBG00J4XKS07PCLO:CV · BBG00J4XKS34PCLO:CJ · BBG00J4XKS70PCLO:TV · BBG00J4XKSB5PCLO:TN · BBG00J4XKSF1PCLO:TG · BBG00J4XKSG0PCLO:TK · BBG00J4XKSH9PCLO:TW · BBG00J4XKSJ7PCLO:DV · BBG00J4XKSM3PCLO:DS · BBG00J4XKSN2PCLO:DG · BBG00J4XKSQ9PCLO:QF · BBG00J4XKSR8

All fundamentals and in-depth analysis of Pharmacielo

Our stock analysis for Pharmacielo stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pharmacielo. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.